Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342022 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ACHEPTPN1FFAR4CYP3A4 | |
| SCHEMBL2955343 | 0.79 | ALDH1A1 (0.56) | ALDH1A1ACHEPTPN1FFAR4CYP3A4 | |
| SCHEMBL25620251 | 0.77 | PTPN1 (0.46) | ALDH1A1ACHEPTPN1TDP1DHFR | |
| SCHEMBL24434 | 0.76 | ACHE (0.52) | ALDH1A1ACHECYP3A4MAPTCA9 | |
| SCHEMBL6732214 | 0.74 | ALDH1A1 (0.40) | ALDH1A1HTT | |
| SCHEMBL5877432 | 0.74 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CA9 | |
| SCHEMBL1277202 | 0.73 | CA1 (0.48) | ALDH1A1ACHECYP3A4MAPT | |
| SCHEMBL14120989 | 0.71 | ALDH1A1 (0.52) | ALDH1A1ACHEPTPN1FFAR4TDP1 | |
| SCHEMBL16685634 | 0.71 | THRA (0.40) | ALDH1A1CYP3A4MAPT | |
| SCHEMBL23744 | 0.71 | CA12 (0.45) | ALDH1A1ACHESMN1; SMN2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-112470045-A | Optical filter and display device | 住友化学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| CN-112469695-A | Compound and method for producing same | 住友化学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-2073816-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-6900213-B2 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1351941-B1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA, LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | ALDH1A1 4410/4885ACHE 4318/4885PTPN1 638/4885 |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | FSHR, GNRHR, LHCGR | ALDH1A1 1222/4885ACHE 2514/4885PTPN1 2503/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ALDH1A1 444/4885ACHE 689/4885PTPN1 3979/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ALDH1A1 4305/4885ACHE 4206/4885PTPN1 784/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | ALDH1A1 3748/4885ACHE 3993/4885PTPN1 412/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ALDH1A1 4305/4885ACHE 4206/4885PTPN1 784/4885 |
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | ALDH1A1 1458/4885ACHE 3099/4885PTPN1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.